Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 2 ... product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded, dendriticcell-based immunotherapy that is perfectly matched to each patient's unique HIV viral ... Argos Therapeutics announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ...
2009 NOV 1 ... a product of the Company's Arcelis™ technology, and is a personalized, RNA-loaded dendriticcell-based immunotherapy that is perfectly matched to each patient's unique HIV viral ... Argos Therapeutics announced the presentation of two abstracts at the AIDS Vaccine 2009 conference, being held October 19-22 in Paris, France. Favorable immune response, ...
2009 NOV 23 ... that LEAPS peptide immunogens can convert precursor cells from mouse or humans to become dendritic cells (DC), the cell that directs the subsequent immune response. These DCs produce ... in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The data was presented at the 7th GTCbio Vaccine: "All Things Considered" ...
2009 NOV 16 ... to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system ... therapeutic cancer vaccines based on its patented ImmunoBody® platform, SCIB1 DNA vaccine has been successfully completed ahead of the planned clinical trials that are expected ...
2009 NOV 23 ... processing and presentation by professional antigen-presenting cells, particularly dendritic cells (DC)," scientists writing in the journal Clinical and Vaccine Immunology report. ... "Human immunodeficiency virus type 1 (HIV-1)-specific T-cell reactivity has been related to protection from disease progression. Optimal T-cell ...
2009 NOV 2 ... is newly published data in Gene Therapy. According to a study from the United States, "Dendritic cells (DC) engineered in vitro by DNA encoding OVAhsp70 and IL-15 up-regulated their ... long-lasting Th1 and CTL responses and anti-B16OVA activity." "CD8T cell-mediated primary tumor protection was abrogated by DC or CD4T cell depletion during the ... A report, 'Transcriptional IL-15-directed in vivo DC targeting DNA vaccine,' is newly published data in Gene Therapy. According to a study from the United States, ...
2009 NOV 2 ... Investigators publish new data in the report 'Improvement of a dendriticcell-based tumour vaccine by an influenza virus.' "Induction of cytotoxic T cells by ...
2009 NOV 23 ... that induce pathogen-specific CTL in the lung are poorly explored." "Dendritic cells (DC) have increasingly been exploited as vaccines against infections. However, few ... According to recent research published in the American Journal of Respiratory Cell and Molecular Biology, "Effective protective immunity against respiratory infections ... CTL responses in the lung. Our objective was to develop an efficacious mucosal DC vaccine to generate protective CTL against respiratory infections with intracellular pathogens. ...
2009 NOV 9 ... Geron scientists published data in the journal Regenerative Medicine demonstrating that dendritic cells (DCs) scalably manufactured from human embryonic stem cells (hESCs) exhibit the ... (FDA) placed Geron's IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, on clinical hold ... in the bloodstream. These findings support the use of hESC-derived DCs in therapeutic vaccine applications for cancer and other diseases. The U.S. Food and Drug ...
2009 NOV 9 ... additional data from its Phase I clinical trial evaluating ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme ...
2009 NOV 2 ... own immune system to fight cancer. DCVax=AE-Brain is made up of the patient's own "dendritic cells," the master cells which direct the immune system, that have been activated and ... injection in the upper arm, under the skin, similar to a flu shot or insulin shot. These cell treatments are administered at a series of time points several weeks apart and then ... results are random. DCVax=AE-Brain is a groundbreaking personalized vaccine designed to stimulate a patient's own immune system to fight cancer. DCVax=AE-Brain is ...
2009 NOV 16 ... vaccine site and the tumor site by CD8(+) T cells and ''sentinel'' and plasmacytoid dendritic cells. Gvax and Fl3vax did not synergize when used in combination in treating B16 ... "The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations and aberrations in gene ...
2009 NOV 1 ... of malaria-naive subjects, resulting in an alternative activation of monocyte-derived dendritic cells and induction of a pro-inflammatory response by stimulated PBMCs." ... "Although there is evidence, from human and animal malaria model systems that cell-mediated immunity may contribute to both protection and pathogenesis, the knowledge on ... merozoite protein and is currently considered a major candidate antigen for a malaria vaccine. Previously, we showed that AMA-1 has an influence on cellular immune responses of ...
2009 NOV 23 ... 0.001). Moreover, PIC alone and RA-PIC robustly promoted the formation of the follicular dendriticcell (FDC) network in the GC light zone. PIC and RA-PIC also increased IgG1-positive B ... nutritional-immunological combination could be an effective means of promoting a robust vaccine response." Ma and colleagues published their study in Clinical and Vaccine ...
2009 NOV 2 ... response of HA-specific CD4(+) T cells when it was coimmunized with the HA epitope. Dendritic cells treated in vitro with GK1 were capable of enhancing T-cell activation. ... cysticerci, enhances the immunogenicity of the commercial inactivated influenza vaccine Fluzone in both young and aged mice. In particular, antibody responses were much ...
2009 NOV 23 ... and in patients with hematological malignancies. The interactions between human immature dendritic cells (iDCs) and Aspergillus fumigatus antigens are widely uncharacterized," ... aspergillosis is a significant cause of morbidity and mortality in patients after stem cell transplantation, in solid organ transplant recipients, and in patients with ... of A. fumigatus." Ok and colleagues published their study in Clinical and Vaccine Immunology (Immune Responses of Human Immature Dendritic Cells Can Be Modulated by the ...
2009 NOV 23 ... According to recent research from Iran, "The use of dendritic cells (DCs) as a cellular adjuvant is a promising approach to the immunotherapy of ... published their study in Clinical and Vaccine Immunology (Improvement of a Dendritic Cell-Based Therapeutic Cancer Vaccine with Components of Toxoplasma gondii. Clinical and ...
2009 NOV 16 ... team expanded their work to examine more specific cell types, including macrophages and dendritic cells which are responsible for activating anti-pathogen B and T cell responses. They ... reacts the same way," says Barber. The theory is that without STING, a DNA-based vaccine wouldn't have the effectiveness because the body would not create interferon and other ...
